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Abstract
Background: Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a
high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin
are not well defined.
Methods: A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and
safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus
meropenem (2 g every 8 h), both in combination with levofloxacin (500mg every 12 h) for 7–14 days in patients with
late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The
primary endpoint was mortality at 28 days after randomization in the microbiologically modified intention-to-treat
(mMITT) population. Secondary outcomes included clinical and microbiological cure, renal function at the end of the
treatment, and serious adverse events. The study was interrupted after the interim analysis due to excessive
nephrotoxicity in the colistin group; therefore, the sample size was not achieved.
Results: A total of 157 (67.7%) patients were included in the mMITT population, 36 of whom (22.9%) had VAP caused
by CR-GNB. In the mMITT population, no significant difference in mortality between the colistin group (19/82, 23.2%)
and the meropenem group (19/75, 25.3%) was observed, with a risk difference of − 2.16 (− 15.59 to 11.26, p = 0.377);
the noninferiority of colistin was not demonstrated due to early termination and limited number of patients infected
by carbapenem-resistant pathogens. Colistin plus levofloxacin increased the incidence of renal failure (40/120, 33.3%,
versus 21/112, 18.8%; p = 0.012) and renal replacement therapy (11/120, 9.1%, versus 2/112, 1.8%; p = 0.015).
Conclusions: This study did not demonstrate the noninferiority of colistin compared with meropenem, both combined
with levofloxacin, in terms of efficacy in the empirical treatment of late VAP but demonstrated the greater nephrotoxicity of
colistin. These findings do not support the empirical use of colistin for the treatment of late VAP due to early termination.
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Background
Ventilator-associated pneumonia (VAP) is considered one
of the most common hospital-acquired infections and the
leading infectious cause of mortality in intensive care units
(ICUs) [1]. Multidrug-resistant gram-negative bacilli
(MDR-GNB), including Pseudomonas aeruginosa, Acineto-
bacter baumannii, and extended-spectrum beta-lactamase
(ESBL)-producing or carbapenemase-producing Enterobac-
teriaceae, are currently the pathogens most frequently iso-
lated from patients with late VAP in some countries [2, 3].
VAP caused by MDR-GNB is associated with high mortal-
ity, and appropriate empirical therapy is crucial for survival
[4–6]. In addition, inappropriate antimicrobial treatment is
administered more frequently to patients with VAP caused
by these pathogens [7].
Thus, the management of patients highly suspected of
having VAP caused by MDR-GNB remains an unre-
solved challenge. Carbapenems have been the backbone
for the treatment of these infections, but the develop-
ment of strains resistant to these antimicrobials raises
concerns regarding their use. Currently, colistin is the
antimicrobial with the greatest in vitro activity against
carbapenem-resistant (CR)-GNB, and recent guidelines
from Infectious Disease Society of America [8] and
European Respiratory Society [9] recommend colistin
combined with other antipseudomonal agents as a thera-
peutic option for the empirical treatment of VAP in
units with high rates of resistance to antimicrobial
agents from other classes, especially if Acinetobacter is
the likely pathogen. Both expert panels recognize that
no previous randomized clinical trial assessing colistin as
empirical therapy for VAP has been published, which is
a major limitation.
Clinical experience with colistin has resulted in contra-
dictory findings. In some studies, the clinical efficacy of
colistin was similar to that of beta-lactam antibiotics [10,
11]. Conversely, in others reports, colistin was found to
be less effective and more toxic [12].
Three meta-analyses assessed the efficacy and safety of
colistin for the treatment of VAP caused by MDR-GNB
and concluded that colistin appears to be as effective and
safe as beta-lactam antibiotics [13–15]. However, these
meta-analyses have important limitations: the quality of
the included studies is low, including observational stud-
ies; the results from studies with inhaled colistin are com-
bined with those for intravenous colistin; and the drug
combinations are highly variable.
Finally, three clinical trials have been performed to
evaluate the use of intravenous colistin. One trial com-
pared ampicillin/sulbactam and colistin for the treatment
of MDR A. baumannii VAP but had a very small sample
size of 28 patients [16]. Another study compared colistin
monotherapy and colistin combined with rifampin in 210
patients with serious infections caused by extensively
drug-resistant A. baumannii [17]. The third study
compared colistin alone versus colistin plus meropenem
for the targeted treatment of severe infections caused by
CR-GNB in 406 patients, 207 of whom had VAP [18].
However, no clinical trial has been performed to evaluate
the efficacy and safety of intravenous colistin for the em-
pirical treatment of serious infections, including VAP.
We aimed to compare the efficacy and safety of empir-
ical treatment with intravenous colistin versus merope-
nem in patients with late VAP in settings with a high
prevalence of CR-GNB using a randomized trial design.
Methods
Study design and patients
Magic Bullet is an investigator-driven, open-label, random-
ized controlled noninferiority trial conducted from May
2012 to November 2015. Thirty-two hospitals participated
in the study—17 in Spain, 10 in Greece, and 5 in Italy. The
study protocol has been published previously [19].
Patients were eligible if they were 18 years of age or older,
developed VAP after at least 96 h on mechanical ventilation
or less than 96 h on mechanical ventilation if they had previ-
ously received antibiotic treatment for at least 5 days, and
were hospitalized for more than 7 days. VAP was defined as
new or progressive pulmonary infiltrates on a chest X-ray
suggestive of pneumonia with no other probable cause in
combination with at least one of the following characteris-
tics: fever, an elevated (> 10,000/mm) total peripheral white
blood cell (WBC) count, immature neutrophils (bands)
higher than 15% regardless of the total peripheral WBC
count, leukopenia with a total WBC count less than 4500/
mm, new onset of expectorated or suctioned respiratory se-
cretions characterized by a purulent appearance indicative
of bacterial pneumonia, or a Modified Clinical Pulmonary
Infection Score (CPIS) > 4.
Specific exclusion criteria included the isolation of colis-
tin- or meropenem-resistant GNB cultures from respiratory
samples from surveillance cultures in the 7 days before in-
clusion, as well as the use of meropenem. The complete
Cisneros et al. Critical Care          (2019) 23:383 Page 2 of 13
inclusion and exclusion criteria are detailed in
Additional file 1.
The study was conducted in accordance with the Dec-
laration of Helsinki and with the legal norm directive
2001/20/EC of the European Parliament relating to the
implementation of Good Clinical Practice. The institu-
tional ethics committee at each study site approved the
protocol, and the regulatory authorities of the three
countries provided authorization. All patients or their
legal surrogates provided written informed consent prior
to study enrollment.
The study was monitored for safety by the Data Safety
Monitoring Board (DSMB) and assessed when 50% of the
sample size was recruited to detect and report early
evidence of a prespecified or unanticipated benefit or detri-
ment to trial participants that may be attributable to one of
the treatments under evaluation to determine recommenda-
tions concerning continuation or conclusion of the trial
[19]. The trial was registered with ClinicalTrials.gov,
number NCT01292031, and with EudraCT, number 2010-
023310-31.
Randomization and masking
After confirmation of the inclusion/exclusion criteria by
the local principal investigator in an electronic case re-
port form, patients were randomized to receive colistin
or meropenem in a 1:1 allocation using an automatic
system integrated into the electronic case report form.
The overall study population included all patients who
were enrolled, randomly assigned, and received at least
one dose of the study medication constituted the modi-
fied intention-to-treat (MITT) population.
Randomization was stratified by patient severity at the
time of VAP diagnosis measured with the Acute Physi-
ology and Chronic Health Evaluation (APACHE) score (≤
15 or > 15) and by clinical site. Given the open-label trial
design, masking was not applicable.
Procedures
Patients received either colistin methanesulfonate through
a 1-h intravenous infusion at a loading dose of 4.5 million
units (MIU), followed by 3 MIU maintenance doses every
8 h in a 30-min infusion, or meropenem at a dose of 2 g
administered intravenously (i.v.) every 8 h in a 30-min in-
fusion. In addition, all patients received levofloxacin (500
mg i.v. every 12 h in a 30-min infusion). For patients with
moderate renal dysfunction at baseline, the colistin dosage
was adjusted as follows: 2 MIU every 12 h with a creatin-
ine clearance (CrCl) of 50–90ml/min, and 2 MIU every
24 h with a CrCl of 10–50 ml/min following the for-
mula of Gounden et al. [20]. For patients with a CrCl
of 10–50 ml/min, the dose of meropenem was re-
duced to 1 g every 12 h, and levofloxacin was reduced
to 250 mg every 12 h.
The combination with levofloxacin in both groups was
based on the results of the clinical trial of Heyland et al.
[21], which suggested that for patients at a high risk of
MDR-GNB, meropenem and ciprofloxacin combination
therapy is safe and may be associated with better micro-
biological and clinical outcomes.
The drugs used in this study were commercial prepara-
tions of colistin and meropenem. Colistin is manufactured
by G.E.S., Genéricos Españoles, Madrid (Spain), and mero-
penem is manufactured by Fresenius Kabi España, Barce-
lona (Spain). Both drugs were purchased and labeled for
the study. Antimicrobials with activity against methicillin-
resistant Staphylococcus aureus (vancomycin or linezolid)
were administered at the investigator’s discretion [19].
A respiratory sample for microbiological diagnosis was
obtained from all patients before randomization. The
method used (bronchoalveolar lavage (BAL) or tracheal
aspirate) was freely selected by the investigator. All sam-
ples were processed quantitatively. The cutoff values
used to diagnose pneumonia were > 106 colony-forming
units per ml (CFU/ml) for conventional tracheal aspi-
rates and > 104 CFU/ml for BAL fluid. A set of two
blood cultures was also obtained to determine the pres-
ence of bacteremia. Once the microbiological results
from baseline samples were available, the therapy was
adapted to the culture results. As a general rule, physi-
cians were advised to prescribe a single antibiotic with
the narrowest spectrum that had activity against the in-
fecting organism as soon as possible.
To evaluate a microbiological cure, a tracheal aspirate
or a sputum culture was collected if the patient remained
on mechanical ventilation or if the patient breathed spon-
taneously, at 72 h, at 8 days, at the end of treatment, and
at 28 days after randomization. Pathogen identification
and susceptibility testing for all isolates were performed
by the local laboratory. To test the susceptibility to colistin
in most hospitals participating in the study, commercial
microdilution was used (83%), and in the remaining hospi-
tals, gradient strips were used (17%). Colistin monitoring
was not performed for dosing adjustments.
Assessments of clinical symptoms and physical findings,
sample collection, and evaluations of efficacy and safety
variables, including renal function monitoring (CrCl and
renal replacement therapy) and adverse events, were
conducted at the baseline evaluation, at 72 h, at 8 days, at
the end of treatment, and at 28 days after randomization.
Outcomes
The primary outcome of efficacy was determined accord-
ing to the proportion of patients in the MITT population
with microbiologically confirmed (microbiologically modi-
fied intention-to-treat, mMITT) VAP who died from any
cause 28 days after randomization.
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The secondary outcomes included 28-day all-cause mor-
tality; clinical cure; renal function at the end of treatment,
including post hoc renal failure based on the RIFLE score
[22]; adverse events in the MITT population; and microbio-
logical cure in the mMITT population. A post hoc analysis
of mortality in the group with CR-GNB VAP was added.
Clinical cure was defined as complete resolution of all signs
and symptoms of VAP at 28 days after randomization.
Microbiological cure was defined as eradication of the
pathogen causing VAP at 28 days after randomization.
Adverse events included any serious treatment-
emergent adverse events (SAEs), suspected SAEs related
to a study medication (according to the investigator’s
opinion), and serious unexpected adverse events up to
28 days after the last dose of the study medication.
Statistical analysis
The noninferiority of colistin was confirmed if the lower
limit of the two-sided 95% confidence interval (CI) for the
difference in mortality rates (colistin minus meropenem) in
the mMITT population was less than or equal to 10% [23].
On the assumption of a success rate of 20% mortality [21],
a sample of 198 patients who could be evaluated in each
treatment group (a total of 396) was required to demon-
strate noninferiority at the two-sided significance level of
5% with a power of 80%. Considering that the microbio-
logical diagnosis of VAP is obtained in approximately 80%
of episodes [21], a 25% increase in the sample size is
required. Thus, a total of 496 individuals were needed. The
primary analysis was performed by intention-to-treat in the
mMITT and MITT populations.
Continuous variables were reported as the means
(standard deviations (SD)) or the medians (interquartile
ranges), and categorical variables were reported as num-
bers (%). For dichotomous efficacy outcomes, risk ratios
(RRs) and risk differences for the primary and secondary
endpoints with 95% CIs were calculated with Cochran’s
Mantel-Haenszel method for estimation of the common
treatment effect. A Kaplan–Meier curve was plotted for
time to death until day 28 for the mMITT and MITT
populations. A p value < 0.05 was considered significant.
Statistical analysis was performed using SPSS version
19.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Based on the results from the interim analysis with half
of the sample size achieved, the DSMB suggested stop-
ping the clinical trial considering that continuation could
be a risk for the safety of patients due to the high
nephrotoxicity observed in the colistin group. Following
this suggestion, the trial was stopped on October 13,
2015, and this decision was communicated to the ethics
committees in the three countries participating in the
study. The last patient visit was performed on November
3, 2015.
Of the 892 patients screened for eligibility from May
2012 to October 2015, 657 were excluded, mainly due to
previous use of meropenem (120/657, 18.3%). Detailed
reasons for exclusion are depicted in Fig. 1. A total of
235 patients were randomized. Three patients were
excluded after randomization but before receiving the
study medication: two were excluded for receiving renal
replacement therapy at randomization, and one was
excluded for having received meropenem therapy prior
to inclusion. Finally, 232 patients were analyzed for
intention-to-treat in the MITT population; 120 (51.7%)
were randomly allocated to the colistin plus levofloxacin
group (colistin group), and 112 (48.3%) were randomly
allocated to the meropenem plus levofloxacin group
(meropenem group) (Fig. 1).
At the time of VAP diagnosis, the baseline characteris-
tics of the patients (age, sex, underlying diseases, clinical
presentation, APACHE score, radiographic film, CPIS,
renal function, bacteremia, and microbiological diagno-
sis) were similar in both groups (Table 1).
VAP was microbiologically confirmed in 157/232
(67.7%) patients, who represent the mMITT population;
82 (52.2%) patients were included in the colistin group,
75 (47.8%) patients were included in the meropenem
group, and 36 patients (22.9%) had VAP caused by CR-
GNB. In the respiratory samples, the microbiological
diagnosis of VAP was confirmed in 141/208 (68%) of the
tracheal aspirates and in 16/24 (67%) of the BAL sam-
ples. Bacteremia was detected in 38/232 (16.4%) cases of
VAP, and the etiology of VAP was polymicrobial in 55/
157 (35.0%) patients (Table 2).
In total, 212 bacteria were isolated, mainly GNB (174/
212, 82.0%). The most frequent GNB were P. aeruginosa,
A. baumannii, and Klebsiella pneumoniae (97/212, 45.8%).
Of them, 37/97 (38.1%) were CR, and 12/97 (12.4%) were
colistin resistant. All pathogens isolated at study entry are
presented in Table 2.
Optional empirical treatment with linezolid or vanco-
mycin and appropriate empirical treatment received
31.4% (73/232) and 75.8% (119/157), respectively. The
duration of therapy was higher in the colistin group (9
days (5 to 14)) than in the meropenem group (7.9 days
(5 to 11), p = 0.035) (Table 1).
For the primary outcome, all-cause mortality within
28 days after randomization in the mMITT population,
no significant difference was observed between the colis-
tin (19/82, 23%) and meropenem groups (19/75, 25%)
(p = 0.752). The risk ratio for mortality with colistin was
0.91% (0.52 to 1.59), and the risk difference was − 2.16%
(− 15.59 to 11.26), exceeding the noninferiority margin
of 10% (Table 3 and Fig. 2). No survival benefit was ob-
served in the mMITT population (log rank (Mantel-
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Cox) p = 0.75) (Fig. 3a) or in the MITT population (log
rank (Mantel-Cox) p = 0.85) (Fig. 3b).
Regarding mortality and clinical cure in the MITT
population, microbiological cure in the mMITT popula-
tion, mortality among patients infected with CR-GNB,
and mortality depending on MIC of meropenem/colistin,
no significant differences between groups were observed
(Fig. 2, Tables 3 and 4).
A higher incidence of renal failure at the end of treat-
ment compared with randomization, mainly correspond-
ing to the risk and injury categories of RIFLE (40/120,
33.3%, versus 21/112, 18.8%; p = 0.012), was observed in
patients treated with colistin plus levofloxacin. At the
end of treatment, ClCr was significantly lower in the co-
listin group than in the meropenem group (90.9 (57.2–
141.9) versus 122.3 (86.1–185.7) ml/min, p = 0.003), and
a significantly higher proportion of patients in the colis-
tin group needed renal replacement therapy (11/120,
9.1%, versus 2/112, 1.8%; p = 0.015) (Table 3). The evolu-
tion of renal function, which was measured according to
baseline ClCr versus ClCr at the end of treatment, did
not change significantly in the colistin group (101.0
(70.9–131.0) versus 90.9 (57.2–141.9) ml/min, p = 0.724)
and improved in the meropenem group (113.0 (66.8–
163.1) versus 122.3 (86.1–185.7) ml/min, p ≤ 0.001). In
the colistin arm, the incidence of any form of nephro-
toxicity was not statistically different (p = 0.443) if the
empirical regimen included vancomycin (15.8%), linezo-
lid (35.3%), or no active antibiotic against methicillin-
resistant Staphylococcus aureus (31%).
A total of 95 (40.9%) patients presented SAEs, and 5 (2.2%)
patients showed SAEs suspected of being related to a study
medication. The frequency of SAEs was similar in both
groups, and no serious unexpected adverse events were noted.
Detailed comparisons of the primary and secondary outcomes
according to the treatment groups are shown in Table 3.
Discussion
This clinical trial is the first to analyze the efficacy and
safety of intravenous colistin in the empirical treatment of
late VAP. The results do not demonstrate the noninferior-
ity of colistin compared with meropenem, both of which
were combined with levofloxacin due to early termination.
However, nephrotoxicity was significantly higher with
Fig. 1 Flow chart. *One patient was excluded from the analysis due to incorrect inclusion (renal replacement therapy). **Two patients were
excluded from the analysis due to incorrect inclusion (renal replacement therapy and previous use of meropenem). GNB: gram-negative bacilli;
CABP: community-acquired bacterial pneumonia; HIV/AIDS: human immunodeficiency virus infection and acquired immune deficiency syndrome;
CPIS: Clinical Pulmonary Infection Score; VAP: ventilator-associated pneumonia
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Table 1 Patient, infection, and treatment characteristics
Colistin + levofloxacin
group (n = 120)
Meropenem + levofloxacin
group (n = 112)
p value
Age, years (n = 232) 63 [49–71] 60.5 [50–70] 0.370
Female (n = 232) 28 (23.3) 31 (27.7) 0.448
Underlying diseases (n = 232) 41 (34.2) 38 (33.9) 0.969
Diabetes mellitus 19 (15.8) 22 (19.6) 0.447
Chronic liver disease 6 (5.0) 5 (4.5) 0.848
Congestive heart failure 2 (1.7) 2 (1.8) 0.945
Chronic renal disease 1 (0.8) 4 (3.6) 0.151
Chronic obstructive pulmonary disease 21 (17.5) 10 (8.9) 0.055
Neoplasia 5 (4.2) 3 (2.7) 0.535
Infection characteristics (n = 232)
Days from MV to VAP 8 [6–11] 7.5 [6–11] 0.844
Clinical presentation
Sepsis 67 (55.8) 62 (55.4) 0.992
Severe sepsis 27 (22.5) 26 (23.2)
Septic shock 26 (21.7) 24 (21.4)
APACHE II trial inclusion—VAP diagnosis 19 [14–24] 17 [13–22] 0.065
APACHE II ≤ 15 40 (33.3) 46 (41.1) 0.223
APACHE II > 15 80 (66.7) 66 (58.9)
Multilobar infiltrates (Rx film) 69 (57.5) 54 (48.2) 0.157
Baseline CPIS 6 [4–7] 5 [4–7] 0.662
Baseline creatinine clearance (mg/h) (n = 231) 101.0 [70.9–131.0] 113.0 [66.8–163.4] 0.424
Microbiological diagnosis (n = 157) 82 (52.2) 75 (47.8) 0.824
VAP caused by A. baumannii, P. aeruginosa, and K. pneumoniae (n = 79) 40 (48.8) 39 (52) 0.811
MIC distribution
Meropenem MIC
≤ 2mg/l—susceptible 16 (40) 18 (46.2) 0.719
> 2–8 mg/l—intermediate 4 (10) 5 (12.8)
> 8 mg/l—resistant1 20 (50) 16 (41)
Colistin MIC
≤ 2mg/l—susceptible2 35 (87.5) 32 (82.1) 0.500
> 2 mg/l—resistant 5 (12.5) 7 (17.9)
Levofloxacin MIC
≤ 2mg/l—susceptible 16 (40) 17 (43.6) 0.746
> 2 mg/l—resistant 24 (60) 22 (56.4)
Bacteremia (n = 232) 21 (17.5) 17 (15.2) 0.633
Treatment (n = 232)
Empirical treatment with vancomycin 19 (15.8) 19 (17) 0.816
Empirical treatment with linezolid 17 (14.8) 18 (16.4) 0.744
Appropriate empirical antibiotic treatment (n = 157) 65 (79.3) 54 (72) 0.288
Duration of antibiotic treatment
Days of treatment (n = 232) 9 [5–14] 7.9 [5–11] 0.035
Days of levofloxacin (n = 232) 8 [5–13] 7 [4–9] 0.003
The data are expressed as n, n (%), and the median (IQR) unless otherwise indicated
MV mechanical ventilation, VAP ventilator-associated pneumonia, APACHE Acute Physiology and Chronic Health Evaluation, Rx radiographic film, GNB gram-
negative bacilli, CPIS Clinical Pulmonary Infection Score
1Definition according to the EUCAST 2012 recommendations and criteria. Carbapenem-resistant gram-negative bacteria (MIC > 8mg/l). Colistin-resistant gram-
negative bacteria (MIC > 2mg/l for A. baumannii and Enterobacteriaceae and > 4mg/l for P. aeruginosa). EUCAST. Breakpoint tables for interpretation of MICs and
zone diameters version 2.0, valid from 2012 to 01-01. http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/
2Includes P. aeruginosa; all of these isolates had an MIC breakpoint ≤ 4 mg/l (susceptible)
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colistin. This information is crucial in the era of anti-
microbial resistance, where the empirical use of colistin
for VAP is increasingly common in clinical practice.
This clinical trial analyzed the efficacy and safety of
colistin in the empirical treatment of VAP in settings
with a high prevalence of CR-GNB. Both treatment
groups were similar when comparing the baseline condi-
tions of the patients (age, sex, and underlying diseases),
clinical manifestations (mechanical ventilation time, dis-
ease severity), microbiological characteristics (etiological
diagnosis, CR-GNB, and bacteremia), and treatment at
the time of randomization (appropriate empirical treat-
ment and the use of vancomycin or linezolid). These
baseline characteristics are similar to the characteristics
of patients included in other clinical trials investigating
VAP [21, 24, 25] and confirm the current predominance
of GNB (81.6%) as the etiology of this infection and the
high frequency of CR-GNB (23.5%) in some countries.
The mortality rates of the patients were similar in both
groups (22.5% in the colistin group versus 21.4% in the
meropenem group, p = 0.844). Comparing the mortality
rate found in this study with those reported in other stud-
ies is difficult due to the heterogeneity across studies.
Heyland et al. [21] described overall mortality rates of
18.7% and 26.8% for VAP by MDR-GNB, and Kollef et al.
[24] described a mortality rate of 20%, all of which are
higher than the 10% and 8% mortality rates reported in two
studies on nosocomial pneumonia [25, 26].
These differences among studies indicate that the prog-
nostic factors of VAP, which are as important as the APA-
CHE score, as well as those of bacteremia and MDR bacteria
are all different. In Chastre et al.’s study, the average APA-
CHE score was 14.7, and the bacteremia rate was 4.5% [25].
In our study, the APACHE score was 18, and the
bacteremia rate was 16%. In addition, in our study,
the frequency of septic shock was 21.6%. The mortal-
ity rate of VAP caused by CR-GNB is higher than
that caused by susceptible bacteria. Therefore, in our
study and in Paul et al.’s trial, the mortality rates
were 30.6% and 44%, respectively [18].
In this study, the rate of microbiological cure was poor
at 56% in both groups, which is similar to the rate of
54% (30/56) described by Heyland et al. [21] in a sub-
group of patients infected with difficult-to-treat GNB,
demonstrating the difficulty associated with eradicating
these bacteria from the respiratory tract.
Table 2 Overall etiology of ventilator-associated pneumonia and the distributions by group
Pathogens Number (%) Colistin + levofloxacin group (%) Meropenem + levofloxacin
group (%)
Risk ratio (95% CI) p value
Total 212 108 104
Gram-negative bacilli 174 (82.1) 89 (82.4) 85 (81.7)
Acinetobacter baumannii 34 (16.0) 16 (14.8) 18 (17.3) 0.83 (0.39, 1.74) 0.621
Pseudomonas aeruginosa 34 (16.0) 19 (17.6) 15 (14.4) 1.27 (0.60, 2.69) 0.530
Klebsiella pneumoniae 29 (13.6) 14 (13) 15 (14.4) 0.88 (0.40, 1.96) 0.757
Escherichia coli 20 (9.4) 12 (11.1) 8 (7.7) 1.50 (0.58, 4.01) 0.395
Enterobacter aerogenes 13 (6.1) 6 (5.6) 7 (6.7) 0.82 (0.25, 2.60) 0.721
Enterobacter cloacae 10 (4.7) 5 (4.6) 5 (4.8) 0.96 (0.25, 3.68) 0.951
Proteus mirabilis 7 (3.3) 2 (1.9) 5 (4.8) 2.76 (0.52, 14.51) 0.213
Klebsiella oxytoca 6 (2.8) 4 (3.7) 2 (1.9) 0.53 (0.10, 2.94) 0.458
Serratia spp. 5 (2.3) 4 (3.7) 1 (0.9) 0.26 (0.03, 2.37) 0.201
Haemophilus influenzae 4 (1.8) 1 (0.9) 3 (2.9) 3.28 (0.34, 31.96) 0.281
Citrobacter freundii 4 (1.8) 1 (0.9) 3 (2.9)
Citrobacter koseri 3 (1.4) 2 (1.9) 1 (0.9) 0.53 (0.05, 5.94) 0.602
Stenotrophomonas maltophilia 3 (1.4) 2 (1.9) 1 (0.9) 0.53 (0.05, 5.94) 0.602
Achromobacter xylosoxidans 2 (1.0) 1 (0.9) 1 (0.9) 1.07 (0.07, 17.35) 0.961
Gram-positive aerobes 38 (17.9) 19 (17.6) 19 (18.3)
Staphylococcus aureus 26 (12.2) 14 (13) 12 (11.5) 1.14 (0.50, 2.66) 0.751
Enterococcus spp. 8 (3.8) 3 (2.8) 5 (4.8) 1.82 (0.43, 7.81) 0.413
Streptococcus pneumoniae 3 (1.4) 1 (0.9) 2 (1.9) 2.16 (0.19, 24.20) 0.521
Streptococcus sp. 1 (0.004) 1 (0.9) 0 (0.0) – 0.325
Total 212 (100)a 108 (100) 104 (100)
a55 cases of VAP were polymicrobial. CI confidence interval
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In the present trial, the combination of colistin and levo-
floxacin did not meet the noninferiority criterion of less
than or equal to 10% as defined in the protocol, possibly
because the expected sample size was not reached, which
is reflected in the broad confidence interval. In fact, the
efficacy of colistin for the treatment of VAP has been
questioned because of its poor penetration into the lung
parenchyma [27]. The potential for colistin nephrotoxicity
has been a major concern as demonstrated by the contra-
dictory results published in recent studies. In this context,
Table 3 Primary and secondary outcomes
Colistin +
levofloxacin group
Meropenem +
levofloxacin group
Risk ratio (95% CI) for the
outcome with colistin
p value
Efficacy
Primary outcome
Mortality at 28 days in the mMITT population (n = 157) 19/82 (23.2) 19/75 (25.3) 0.91 (0.53, 1.59) 0.752
Secondary outcomes
Mortality at 28 days in the MITT population (n = 232) 27/120 (22.5) 24/112 (21.4) 1.05 (0.65, 1.71) 0.844
Mortality at 28 days with CR-GNB (n = 36) 5/20 (25.0) 6/16 (35.2) 0.67 (0.25, 1.79) 0.425
Clinical cure in the MITT population (n = 232) 82 (68.3) 81 (72.3) 0.94 (0.80, 1.12) 0.507
Microbiological cure in the mMITT population (n = 157) 46 (56.1) 42 (56.0) 1.00 (0.76, 1.32) 0.990
Microbiological failure in the mMITT population (n = 157) 33 (40.2) 31 (41.3) 0.97 (0.67, 1.42) 0.899
Microbiological relapse in the mMITT population (n = 157) 3 (3.7) 2 (2.7) 1.37 (0.24, 7.99) 0.723
Safety
Serious adverse events (n = 232) 50 (41.7) 45 (40.2) 1.04 (0.76–1.41) 0.818
Serious adverse events* (n = 232) 4 (3.3) 1 (0.9) 3.70 (0.42, 32.90) 0.201
CrCl (ml/h) at the end of the treatment day (n = 231) 90.9 [57.2–141.9] 122.3 [86.1–185.7] −37.93 (− 62.96, − 12.90) 0.003
Renal replacement therapy (n = 232) 11 (9.1) 2 (1.7) 5.13 (1.16, 22.65) 0.015
RIFLE score at the end of treatment compared with
randomization (n = 232)μ
n = 120 n = 112 – 0.034¥
None 80 (66.7) 91 (81.3) – –
Risk 21 (17.5) 11 (9.8) – –
Injury 15 (12.5) 5 (4.5) – –
Failure 4 (3.3) 5 (4.5) – –
CI confidence interval, mMITT microbiologically modified intention-to-treat, MITT modified intention-to-treat, CR-GNB carbapenem-resistant gram-negative bacilli,
CrCl creatinine clearance, RRT renal replacement treatment
*Serious adverse events suspected of being related to the study medications according to the investigator’s opinion (4 cases of renal insufficiency/renal
impairment attributed to colistin and 1 case of compartment syndrome related to meropenem), (%) [range]
μNo patients with RRT > 4 weeks (equivalent to RIFLE score of “Loss”) and no patients with permanent dialysis > 3months (equivalent to RIFLE score of “End Stage
Kidney Disease”)
¥p for trend
Fig. 2 Twenty-eight-day all-cause mortality outcomes. mMITT, microbiologically modified intention-to-treat; MITT, modified intention-to-treat; CR-
GNB, carbapenem-resistant gram-negative bacilli. The dotted lines represent the noninferiority margins at ≤ 10%
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Fig. 3 a Survival analysis to day 28 after randomization, the microbiologically modified intention-to-treat population. b Survival analysis to day 28
after randomization, the modified intention-to-treat population
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some studies have shown that the nephrotoxicity rate for
colistin is similar to that for treatment with standard anti-
biotics [13]. In contrast, one observational study showed
threefold higher nephrotoxicity for colistin than for beta-
lactam antibiotics [12].
Our results show that colistin is associated with signifi-
cantly higher nephrotoxicity than meropenem. At the end
of treatment, ClCr was significantly lower in the colistin
group than in the meropenem group (90.9 (57.2–141.9)
versus 122.3 (86.1–185.7) ml/min, p = 0.003), more often
resulted in severe acute renal failure requiring renal re-
placement therapy (9% versus 2%, p = 0.015), and had a
higher incidence of renal failure at the end of treatment. In
our study, we used higher doses of colistin (9 MIU daily for
normal renal function), which may explain this result. In-
deed, an observational study and a clinical trial comparing
this high dose of colistin with low doses of 4 and 6 MIU
daily, respectively, showed that nephrotoxicity is associated
with a high-dose regimen of colistin [28, 29]. Nation et al.
[30] suggest that the dose of colistin needs to be amended
daily for every 10 units of change of the creatinine clearance
to avoid nephrotoxicity. Unfortunately, this method had
not been described when our trial was designed.
The strengths of our study are as follows: the multi-
center design, which supports the external validity of the
findings, and the analysis of efficacy as the primary out-
come based on the mMITT population in which the
diagnosis of VAP required bacteriological confirmation.
Additionally, the etiology of VAP was mainly attributable
to GNB, including CR-GNB; the colistin dosage was up-
dated; and the interim analysis was assessed by the DSMB.
This study also has several limitations. First, the design
was open label due to the need to know the empirical
treatment to guide adjustments when the microbio-
logical diagnosis was received. The evaluation of micro-
biological results was not centralized, and the absence of
a central lab probably increased the heterogeneity of the
microbiological results. We consider the risk of this bias
to be lower than the risk that a delay in receiving the
microbiological results would cause for the patients due
to the inherent delays associated with transporting sam-
ples from 32 centers in 3 different countries. Second,
susceptibility to colistin may cause undetected resistance
when the microdilution method is not used, which was
unknown when the study was designed [31]. The evalu-
ation of some of these isolates in a reference laboratory re-
inforces the idea that colistin and carbapenem resistance
A. baumannii is probably underreported in our study [32].
Third, as we did not perform therapeutic drug monitoring
of meropenem and colistin, target levels may have not
been reached, what occurs in a significant proportion of
critically ill patients with sepsis [33].
Fourth, meropenem was not administered by extended
infusion because when the study was designed, extended
infusion of meropenem was not a quality standard [21].
This recommendation appears in 2016 with the guidelines
from Infectious Disease Society of America which were
published after the end of the study [8]. Fifth, the lack of
data of SOFA score is another limitation that restricts the
chance of quantifying organ function of the patients in-
cluded in this trial lessening the comparability with other
studies. Finally, the calculated sample size was not achieved
because the DSMB suggested early trial termination based
on the interim analysis, and the noninferiority of colistin
could not be demonstrated.
Conclusions
The results of this randomized clinical trial including a
large number of critically ill patients with late VAP caused
mostly by MDR-GNB demonstrate that colistin is more
nephrotoxic than meropenem, both of which were
combined with levofloxacin, and do not demonstrate the
noninferiority of colistin in terms of efficacy due to early
Table 4 Twenty-eight-day mortality per pathogen minimum inhibitory concentration (MIC) in the 79 episodes of A. baumannii,
P. aeruginosa, or K. pneumoniae isolated in respiratory samples obtained at baseline
Colistin + levofloxacin group (n = 120),
death/total number of cases (%)
Meropenem + levofloxacin group (n = 112),
death/total number of cases (%)
p value
VAP caused by A. baumannii, P. aeruginosa,
and K. pneumoniae (n = 79)
40 (48.8) 39 (52) 0.811
MIC distribution
Meropenem MIC
≤ 2 mg/l—susceptible 4/16 (25) 5/18 (27.8) 0.885
> 2–8 mg/l—intermediate 0/4 (0) 0/5 (0) –
> 8mg/l—resistant 5/20 (25) 6/16 (37.5) 0.419
Colistin MIC
≤ 2 mg/l—susceptible 9/35 (25.7) 8/32 (25) 0.947
> 2mg/l—resistant 0/5 (0) 3/7 (42.9) 0.091
MIC minimum inhibitory concentration, VAP ventilator-associated pneumonia
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termination. These findings do not support the empirical
use of colistin in the treatment of late VAP.
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1186/s13054-019-2627-y.
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